Skip to main content

Combination Strategies

Section edited by Paolo A. Ascierto

This section aims to provide a focal point for research that highlights combination therapies, where two or more medications or therapies are strategically combined to improve the treatment of cancer, chronic infections, transplantation and potentially other complex and multi-factorial diseases.

Increasingly detailed understanding of the molecular basis driving complex disease has led to the identifications of new agents that target specific pathways. In some cases treatment of appropriately selected patients has led to striking clinical response, however both primary and secondary resistance mechanisms limited the success of many of these agents. It has become clear that combining or sequencing treatment modalities may enrich the communication between basic biological and immunological sciences and the clinical investigation arena.

Page 1 of 5

  1. The androgen receptor (AR) is a crucial player in various aspects of male reproduction and has been associated with the development and progression of prostate cancer (PCa). Therefore, the protein is the linch...

    Authors: Sherif Mehralivand, Christian Thomas, Martin Puhr, Frank Claessens, Arjanneke F. van de Merbel, Anna Dubrovska, Guido Jenster, Christof Bernemann, Ulrich Sommer and Holger H. H. Erb
    Citation: Journal of Translational Medicine 2024 22:71
  2. Pancreatic ductal adenocarcinoma (PDAC) is a lethal disease. This is due to its aggressive course, late diagnosis and its intrinsic drugs resistance. The complexity of the tumor, in terms of cell components an...

    Authors: Antonio Agostini, Ilaria Guerriero, Geny Piro, Giuseppe Quero, Luca Roberto, Annachiara Esposito, Alessia Caggiano, Lorenzo Priori, Giulia Scaglione, Francesco De Sanctis, Antonella Sistigu, Martina Musella, Alberto Larghi, Gianenrico Rizzatti, Donatella Lucchetti, Sergio Alfieri…
    Citation: Journal of Translational Medicine 2023 21:843
  3. Coronavirus disease 2019 (COVID-19) is an infectious disease caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Since the start of the pandemic, olfactory dysfunction (OD) has been rep...

    Authors: Bian Hu, Mengdan Gong, Yizhen Xiang, Siyuan Qu, Hai Zhu and Dong Ye
    Citation: Journal of Translational Medicine 2023 21:829
  4. While the efficacy of neoadjuvant chemotherapy (NACT) in treating triple-negative breast cancer (TNBC) is generally accepted, not all patients derive benefit from this preoperative treatment. Presently, there ...

    Authors: Mohamed Omar, Pier Vitale Nuzzo, Francesco Ravera, Sara Bleve, Giuseppe Nicolò Fanelli, Claudio Zanettini, Itzel Valencia and Luigi Marchionni
    Citation: Journal of Translational Medicine 2023 21:811
  5. The combination of nivolumab + relatlimab is superior to nivolumab alone in the treatment of naive patients and has activity in PD-1 refractory melanoma. We had previously observed a reduced expression of LAG3 in...

    Authors: Domenico Mallardo, Rachel Woodford, Alexander M. Menzies, Lisa Zimmer, Andrew williamson, Egle Ramelyte, Florentia Dimitriou, Alexandre Wicky, Roslyn Wallace, Mario Mallardo, Alessio Cortellini, Alfredo Budillon, Victoria Atkinson, Shahneen Sandhu, Michielin Olivier, Reinhard Dummer…
    Citation: Journal of Translational Medicine 2023 21:753
  6. Identifying response markers is highly needed to guide the treatment strategy in patients with metastatic melanoma.

    Authors: Domenico Mallardo, Mario Fordellone, Andrew White, Margaret Ottaviano, Francesca Sparano, Michael Bailey, Arianna Bianca Facchini, Sufey Ong, Piera Maiolino, Corrado Caracò, Sarah Church, Ernesta Cavalcanti, Sarah Warren, Alfredo Budillon, Alessandra Cesano, Ester Simeone…
    Citation: Journal of Translational Medicine 2023 21:610
  7. Lung cancer is the leading cause of cancer deaths worldwide. Despite never smokers comprising between 10 and 25% of all cases, lung cancer in never smokers (LCNS) is relatively under characterized from an etio...

    Authors: Peiyao Wang, Sophie Sun, Stephen Lam and William W. Lockwood
    Citation: Journal of Translational Medicine 2023 21:585
  8. The prognosis of esophageal adenocarcinoma (EAC) and gastric adenocarcinoma (GAC) remains poor, and new therapeutic approaches are urgently needed. Claudin 6 (CLDN6) is an oncofetal antigen that is largely abs...

    Authors: Adrian Georg Simon, Su Ir Lyu, Mark Laible, Stefan Wöll, Özlem Türeci, Uğur Şahin, Hakan Alakus, Luca Fahrig, Thomas Zander, Reinhard Buettner, Christiane Josephine Bruns, Wolfgang Schroeder, Florian Gebauer and Alexander Quaas
    Citation: Journal of Translational Medicine 2023 21:552
  9. Novel therapies have achieved unprecedented benefit in survival of advanced melanoma patients. While immunotherapy (ICI) can be administered independent of mutational status, BRAF and MEK kinase inhibitors rep...

    Authors: Reinhard Dummer, Michèle Welti and Egle Ramelyte
    Citation: Journal of Translational Medicine 2023 21:529
  10. Outcomes for patients with melanoma have improved over the past decade with the clinical development and approval of immunotherapies targeting immune checkpoint receptors such as programmed death-1 (PD-1), pro...

    Authors: Paolo A. Ascierto, Sanjiv S. Agarwala, Allison Betof Warner, Marc S. Ernstoff, Bernard A. Fox, Thomas F. Gajewski, Jérôme Galon, Claus Garbe, Brian R. Gastman, Jeffrey E. Gershenwald, Pawel Kalinski, Michelle Krogsgaard, Rom S. Leidner, Roger S. Lo, Alexander M. Menzies, Olivier Michielin…
    Citation: Journal of Translational Medicine 2023 21:508
  11. The activation of dendritic cells (DCs) is pivotal for generating antigen-specific T-cell responses to eradicate tumor cells. Hence, immunotherapies targeting this interplay are especially intriguing. Moreover...

    Authors: Jessica Wenthe, Emma Eriksson, Ann-Charlotte Hellström, Rafael Moreno, Gustav Ullenhag, Ramon Alemany, Tanja Lövgren and Angelica Loskog
    Citation: Journal of Translational Medicine 2023 21:506
  12. Oncolytic virotherapy (OVT) is a promising anti-tumor modality that utilizes oncolytic viruses (OVs) to preferentially attack cancers rather than normal tissues. With the understanding particularly in the char...

    Authors: Xianwang Wang, Yihua Shen, Xingxia Wan, Xiaoqing Hu, Wen-Qi Cai, Zijun Wu, Qiang Xin, Xiaoqing Liu, Jingang Gui, Hong-Yi Xin and Hong-Wu Xin
    Citation: Journal of Translational Medicine 2023 21:500
  13. The discovery and development of novel treatments that harness the patient’s immune system and prevent immune escape has dramatically improved outcomes for patients across cancer types. However, not all patien...

    Authors: Paolo A. Ascierto, Antonio Avallone, Carlo Bifulco, Sergio Bracarda, Joshua D. Brody, Leisha A. Emens, Robert L. Ferris, Silvia C. Formenti, Omid Hamid, Douglas B. Johnson, Tomas Kirchhoff, Christopher A. Klebanoff, Gregory B. Lesinski, Anne Monette, Bart Neyns, Kunle Odunsi…
    Citation: Journal of Translational Medicine 2023 21:488
  14. Viral therapies developed for cancer treatment have classically prioritized direct oncolytic effects over their immune activating properties. However, recent clinical insights have challenged this longstanding...

    Authors: Josef W. Goldufsky, Preston Daniels, Michael D. Williams, Kajal Gupta, Bruce Lyday, Tony Chen, Geeta Singh, Howard L. Kaufman, Andrew Zloza and Amanda L. Marzo
    Citation: Journal of Translational Medicine 2023 21:483
  15. Immune checkpoint inhibitor therapy has revolutionized the clinical management of a diverse range of cancer types, including advanced cutaneous melanoma. While immunotherapy targeting the PD-1/PD-L1 system has...

    Authors: Yue Li, Ben Wu, Md Jakir Hossain, Lily Quagliata, Connor O’Meara, Marc R. Wilkins, Susan Corley and Levon M. Khachigian
    Citation: Journal of Translational Medicine 2023 21:467
  16. Two cycles of neoadjuvant PD-1 blockade plus chemotherapy induced favorable pathological response and tolerant toxicity in patients with locally advanced esophageal squamous cell carcinoma (ESCC). However, app...

    Authors: Guozhen Yang, Xiaodong Su, Yuanheng Huang, Guangyu Luo, Zhiqiang Wang, Peiqiang Cai, Yating Zheng, Ting Bei, Mengli Huang, Yuezong Bai, Haoqiang He, Jin Xiang, Muyan Cai, Jiudi Zhong, Qiyu Guo and Xu Zhang
    Citation: Journal of Translational Medicine 2023 21:411
  17. To evaluate a new class of blood-based biomarkers, anti-frameshift peptide antibodies, for predicting both tumor responses and adverse immune events to immune checkpoint inhibitor (ICI) therapies in advanced l...

    Authors: Luhui Shen, Justin R. Brown, Stephen Albert Johnston, Mehmet Altan and Kathryn F. Sykes
    Citation: Journal of Translational Medicine 2023 21:338
  18. Nivolumab is an anti-PD1 antibody that has dramatically improved metastatic melanoma patients’ outcomes. Nevertheless, many patients are resistant to PD-1 inhibition, occasionally experiencing severe off-targe...

    Authors: Domenico Galati, Serena Zanotta, Mariaelena Capone, Gabriele Madonna, Domenico Mallardo, Marilena Romanelli, Ester Simeone, Lucia Festino, Francesca Sparano, Rosa Azzaro, Rosaria De Filippi, Antonio Pinto, Chrystal M. Paulos and Paolo A. Ascierto
    Citation: Journal of Translational Medicine 2023 21:318
  19. The taxonomy of Kaposi Sarcoma (KS) is based on a classification system focused on the description of clinicopathological features of KS in geographically and clinically diverse populations. The classification...

    Authors: M. R. Openshaw, E. Gervasi, C. A. M. Fulgenzi, D. J. Pinato, A. Dalla Pria and M. Bower
    Citation: Journal of Translational Medicine 2023 21:283
  20. The 2022 Immunotherapy Bridge congress (November 30–December 1, Naples, Italy) featured a Great Debate session which addressed three contemporary topics in the field of immunotherapy. The debates included coun...

    Authors: Paolo A. Ascierto, Renier Brentjens, Samir N. Khleif, Kunle Odunsi, Katayoun Rezvani, Marco Ruella, Ryan J. Sullivan, Bernard A. Fox and Igor Puzanov
    Citation: Journal of Translational Medicine 2023 21:275
  21. The Great Debate session at the 2022 Melanoma Bridge congress (December 1–3) featured counterpoint views from leading experts on five contemporary topics of debate in the management of melanoma. The debates co...

    Authors: Paolo A. Ascierto, Christian Blank, Alexander M. Eggermont, Claus Garbe, Jeffrey E. Gershenwald, Omid Hamid, Axel Hauschild, Jason J. Luke, Janice M. Mehnert, Jeffrey A. Sosman, Hussein A. Tawbi, Mario Mandalà, Alessandro Testori, Corrado Caracò, Iman Osman and Igor Puzanov
    Citation: Journal of Translational Medicine 2023 21:265
  22. Gene expression profiling is increasingly being utilised as a diagnostic, prognostic and predictive tool for managing cancer patients. Single-sample scoring approach has been developed to alleviate instability...

    Authors: Yizhe Mao, Tuba N. Gide, Nurudeen A. Adegoke, Camelia Quek, Nigel Maher, Alison Potter, Ellis Patrick, Robyn P. M. Saw, John F. Thompson, Andrew J. Spillane, Kerwin F. Shannon, Matteo S. Carlino, Serigne N. Lo, Alexander M. Menzies, Inês Pires da Silva, Georgina V. Long…
    Citation: Journal of Translational Medicine 2023 21:257
  23. The mechanism of tumor immune escape and progression in colorectal cancer (CRC) is widely investigated in-vitro to help understand and identify agents that might play a crucial role in response to treatment and i...

    Authors: Nassiba Taib, Maysaloun Merhi, Varghese Inchakalody, Sarra Mestiri, Shereena Hydrose, Karama Makni-Maalej, Afsheen Raza, Fairooz Sahir, Fouad Azizi, Parveen B. Nizamuddin, Queenie Fernandes, Zeenath Safira K. M. Yoosuf, Salam Almoghrabi, Lobna Al-Zaidan, Alaaeldin Shablak, Shahab Uddin…
    Citation: Journal of Translational Medicine 2023 21:235
  24. Head and Neck Squamous Cell Carcinoma is a malignant tumor with high morbidity and mortality. The MMP family plays an important role in tumor invasion and metastasis. However, the mechanistic value of the MMP ...

    Authors: Maohua Liu, Lijuan Huang, Yunling Liu, Sen Yang, Yong Rao, Xiao Chen, Minhai Nie and Xuqian Liu
    Citation: Journal of Translational Medicine 2023 21:208
  25. Prognostic factors for initial response of advanced cutaneous squamous cell carcinoma to cemiplimab treatment are lacking. Il-6 has been found to affect immune cell populations which impact tumor development. ...

    Authors: Domenico Mallardo, Ester Simeone, Lucia Festino, Marilena Tuffanelli, Vito Vanella, Claudia Trojaniello, Maria Grazia Vitale, Margaret Ottaviano, Mariaelena Capone, Gabriele Madonna, Francesca Sparano, Eleonora Cioli, Luigi Scarpato, Marco Palla, Rossella Di Trolio, Paolo Meinardi…
    Citation: Journal of Translational Medicine 2023 21:140
  26. Acral melanoma (AM) is the most common subtype in Chinese melanoma patients with a very poor prognosis. However, our understanding of the disease pathogenesis and molecular landscape is limited by the few stud...

    Authors: Rong Huang, Gaigai Shen, Yu Ren, Kelin Zheng, Jiayu Wang, Yan Shi, Jiani C. Yin, Lanqun Qin, Guiying Zhang, Mengke Zhao, Xinyu Su, Luqiao Li, Fufeng Wang, Yang Shao, Baorui Liu and Zhengyun Zou
    Citation: Journal of Translational Medicine 2023 21:78
  27. Circulating tumor DNA (ctDNA) detection following curative-intent surgery could directly reflect the presence of minimal residual disease, the ultimate cause of clinical recurrence. However, ctDNA is not posto...

    Authors: Zhaoya Gao, Dandan Huang, Hui Chen, Yong Yang, Ke An, Changmin Ding, Zheping Yuan, Zhichao Zhai, Pengfei Niu, Qingkun Gao, Jinping Cai, Qingmin Zeng, Yanzhao Wang, Yuming Hong, Wanshui Rong, Wensheng Huang…
    Citation: Journal of Translational Medicine 2023 21:63
  28. Immunotherapy is a vital treatment for patients with cutaneous melanoma (CM), but effective predictors to guide clinical immunotherapy are lacking. Cuproptosis is a newly discovered mode of cell death related ...

    Authors: Da Liu, Fan Yang, Tongtong Zhang and Rui Mao
    Citation: Journal of Translational Medicine 2023 21:57
  29. Circulating soluble programmed death ligand 1 (sPD-L1) can negatively regulate T-cell function and serve as a prognostic or predictive marker in a variety of cancers. However, rare studies have evaluated the p...

    Authors: Yinjun He, Xiang Zhang, Ming Zhu, Wenguang He, Hanju Hua, Feng Ye, Xile Zhou, Nan Chen, Yandong Li, Weixiang Zhong, Guosheng Wu, Hui Cai and Weiqin Jiang
    Citation: Journal of Translational Medicine 2023 21:25
  30. Chimeric antigen receptor (CAR) T cells and immune checkpoint blockades (ICBs) have made remarkable breakthroughs in cancer treatment, but the efficacy is still limited for solid tumors due to tumor antigen he...

    Authors: Zongliang Zhang, Guoqing Wang, Kunhong Zhong, Yongdong Chen, Nian Yang, Qizhong Lu, Boyang Yuan, Zeng Wang, Hexian Li, Liping Guo, Ruyuan Zhang, Zhiguo Wu, Meijun Zheng, Shasha Zhao, Xin Tang, Bin Shao…
    Citation: Journal of Translational Medicine 2023 21:23
  31. Papillary thyroid cancer (PTC), which is often driven by acquired somatic mutations in BRAF genes, is the most common pathologic type of thyroid cancer. PTC has an excellent prognosis after treatment with conv...

    Authors: Dong Chen, Xi Su, Lizhang Zhu, Hao Jia, Bin Han, Haibo Chen, Qingzhuang Liang, Chenchen Hu, Hao Yang, Lisa Liu, Peng Li, Wei Wei and Yongsheng Zhao
    Citation: Journal of Translational Medicine 2023 21:9
  32. High-grade serous carcinoma (HGSC) is the most common and deadly subtype of ovarian cancer. Although most patients will initially respond to first-line treatment with a combination of surgery and platinum-base...

    Authors: Melissa Bradbury, Eva Borràs, Marta Vilar, Josep Castellví, José Luis Sánchez-Iglesias, Assumpció Pérez-Benavente, Antonio Gil-Moreno, Anna Santamaria and Eduard Sabidó
    Citation: Journal of Translational Medicine 2022 20:611
  33. In this commentary, using existing clinical trial data and FDA approvals we propose that there is currently a critical need for an appropriate balancing between the financial impact of new cancer drugs and the...

    Authors: Tomer Meirson, Valerio Nardone, Francesca Pentimalli, Gal Markel, David Bomze, Maria D’Apolito, Pierpaolo Correale, Antonio Giordano, Luigi Pirtoli, Camillo Porta, Steven G Gray and Luciano Mutti
    Citation: Journal of Translational Medicine 2022 20:593
  34. Despite the recent progress in the treatment and outcome of Non Small Cell Lung Cancer (NSCLC), immunotherapy has still significant limitations reporting a significant proportion of patients not benefiting fro...

    Authors: Carminia Maria Della Corte, Vincenza Ciaramella, Kavya Ramkumar, Giovanni Vicidomini, Alfonso Fiorelli, Valerio Nardone, Salvatore Cappabianca, Immacolata Cozzolino, Federica Zito Marino, Gaetano Di Guida, Qi Wang, Robert Cardnell, Carl Michael Gay, Davide Ciardiello, Erika Martinelli, Teresa Troiani…
    Citation: Journal of Translational Medicine 2022 20:541
  35. Posttranslational protein modifications regulate essential cellular processes, including the immune cell activation. Despite known age-related alterations of the phenotype, composition and cytokine profiles of...

    Authors: Georgiana Toma, Eliza Karapetian, Chiara Massa, Dagmar Quandt and Barbara Seliger
    Citation: Journal of Translational Medicine 2022 20:539
  36. Angiotensin-converting enzyme 2 (ACE2) is a key enzyme of the renin-angiotensin system and a well-known functional receptor for the entry of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) into ho...

    Authors: Xiaoyan Zuo, Sixin Ren, He Zhang, Jianfei Tian, Ruinan Tian, Baoai Han, Hui Liu, Qian Dong, Zhiyong Wang, Yanfen Cui, Ruifang Niu and Fei Zhang
    Citation: Journal of Translational Medicine 2022 20:509
  37. The clinical observation showed a potential additive effect of anti-PD-1 agents and cetirizine in patients with advanced melanoma.

    Authors: Domenico Mallardo, Ester Simeone, Vito Vanella, Maria Grazia Vitale, Marco Palla, Luigi Scarpato, Miriam Paone, Teresa De Cristofaro, Valentina Borzillo, Alessio Cortellini, Francesca Sparano, Sandro Pignata, Francesco Fiore, Corrado Caracò, Piera Maiolino, Antonella Petrillo…
    Citation: Journal of Translational Medicine 2022 20:436
  38. Nephrectomy is considered the backbone of managing patients with localized and selected metastatic renal cell carcinoma (mRCC). The prognostic role of nephrectomy has been widely investigated with cytokines an...

    Authors: Sara Elena Rebuzzi, Alessio Signori, Giuseppe Luigi Banna, Annalice Gandini, Giuseppe Fornarini, Alessandra Damassi, Marco Maruzzo, Ugo De Giorgi, Umberto Basso, Silvia Chiellino, Luca Galli, Paolo Andrea Zucali, Emanuela Fantinel, Emanuele Naglieri, Giuseppe Procopio, Michele Milella…
    Citation: Journal of Translational Medicine 2022 20:435
  39. The immune checkpoint inhibitors (ICIs) combined with other therapeutic strategies have shown exciting results in various malignancies, and ICIs have now become the gold standard for current cancer treatment. ...

    Authors: Dong Shao, Yaping Chen, Hao Huang, Yingting Liu, Junjun Chen, Dawei Zhu, Xiao Zheng, Lujun Chen and Jingting Jiang
    Citation: Journal of Translational Medicine 2022 20:433
  40. The role of germline genetic factors in determining survival from cutaneous melanoma (CM) is not well understood.

    Authors: Mathias Seviiri, Richard A. Scolyer, D. Timothy Bishop, Julia A. Newton-Bishop, Mark M. Iles, Serigne N. Lo, Johnathan R. Stretch, Robyn P. M. Saw, Omgo E. Nieweg, Kerwin F. Shannon, Andrew J. Spillane, Scott D. Gordon, Catherine M. Olsen, David C. Whiteman, Maria Teresa Landi, John F. Thompson…
    Citation: Journal of Translational Medicine 2022 20:403
  41. Advances in immune checkpoint and combination therapy have led to improvement in overall survival for patients with advanced melanoma. Improved understanding of the tumor, tumor microenvironment and tumor immu...

    Authors: Paolo A. Ascierto, Sanjiv S. Agarwala, Christian Blank, Corrado Caracò, Richard D. Carvajal, Marc S. Ernstoff, Soldano Ferrone, Bernard A. Fox, Thomas F. Gajewski, Claus Garbe, Jean-Jacques Grob, Omid Hamid, Michelle Krogsgaard, Roger S. Lo, Amanda W. Lund, Gabriele Madonna…
    Citation: Journal of Translational Medicine 2022 20:391
  42. RET fusions are rare oncogenic drivers in non-small cell lung cancer (NSCLC). While activating RET rearrangements are found in NSCLC patients harboring epidermal growth factor receptor (EGFR) genetic alterations ...

    Authors: Chunyue Wang, Zhenlong Zhang, Yulan Sun, Song Wang, Mengmeng Wu, Qiuxiang Ou, Yang Xu, Zhiming Chen, Yang Shao, Hong Liu and Peifeng Hou
    Citation: Journal of Translational Medicine 2022 20:390
  43. Although the anti-programmed death-1 (PD-1) inhibitor plus chemotherapy combination has been approved as the standard first-line treatment for advanced gastric cancer, a proportion of patients do not significa...

    Authors: Chaorui Wu, Yaopeng Qiu, Renyi Zhang, Xiaoqing Li, Huayuan Liang, Minghao Wang, Fengping Li, Mansheng Zhu, Gengtai Ye, Hao Liu, Guoxin Li and Liying Zhao
    Citation: Journal of Translational Medicine 2022 20:386
  44. Despite the increasing number of treatment options, reliable prognostic/predictive biomarkers are still missing for patients affected by metastatic clear cell renal cell carcinoma (mccRCC).

    Authors: Marzia Del Re, Stefania Crucitta, Federico Paolieri, Federico Cucchiara, Elena Verzoni, Francesco Bloise, Raffaele Ciampi, Chiara Mercinelli, Annalisa Capuano, Liberata Sportiello, Antonia Martinetti, Giuseppe Procopio, Luca Galli, Camillo Porta, Sergio Bracarda and Romano Danesi
    Citation: Journal of Translational Medicine 2022 20:371
  45. The effectiveness of MAPK pathway inhibitors (MAPKi) used to treat patients with BRAF-mutant melanoma is limited by a range of resistance mechanisms, including soluble TNF (solTNF)-mediated NF-kB signaling. so...

    Authors: Cindy A. Sander, Elizabeth A. Rush, Jian Shi, Lidia M. R. B. Arantes, Raymond J. Tesi, Mark A. Ross, Michael J. Calderon, Simon C. Watkins, John M. Kirkwood, Robert L. Ferris, Lisa H. Butterfield and Lazar Vujanovic
    Citation: Journal of Translational Medicine 2022 20:331
  46. Triple negative breast cancer (TNBC) is an aggressive disease characterized by high risk of relapse and development of resistance to different chemotherapy agents. Several targeted therapies have been investig...

    Authors: Stefania Cocco, Alessandra Leone, Maria Serena Roca, Rita Lombardi, Michela Piezzo, Roberta Caputo, Chiara Ciardiello, Susan Costantini, Francesca Bruzzese, Maria José Sisalli, Alfredo Budillon and Michelino De Laurentiis
    Citation: Journal of Translational Medicine 2022 20:290
  47. Malignant mesothelioma (MM) is a rare orphan aggressive neoplasia with low survival rates. Among the other signaling pathways, ErbB receptors and Hh signaling are deregulated in MM. Thus, molecules involved in...

    Authors: Roberto Bei, Monica Benvenuto, Chiara Focaccetti, Sara Fazi, Marta Moretti, Daniela Nardozi, Valentina Angiolini, Sara Ciuffa, Loredana Cifaldi, Raffaele Carrano, Camilla Palumbo, Martino Tony Miele, Riccardo Bei, Giovanni Barillari, Vittorio Manzari, Enrico De Smaele…
    Citation: Journal of Translational Medicine 2022 20:286

Annual Journal Metrics

  • 2022 Citation Impact
    7.4 - 2-year Impact Factor
    6.9 - 5-year Impact Factor
    1.458 - SNIP (Source Normalized Impact per Paper)
    1.544 - SJR (SCImago Journal Rank)

    2022 Speed
    10 days submission to first editorial decision for all manuscripts (Median)
    84 days submission to accept (Median)

    2022 Usage 
    4,243,080 downloads
    32,614 Altmetric mentions